Publication & Citation Trends
Most Cited Works
Publications
59 total
Real-world time to next treatment in metastatic urothelial cancer patients: Enfortumab vedotin and pembrolizumab vs chemotherapy as first-line treatment.
Cited by 0
Semantic Scholar
Clinical outcomes in the real-world utilization of 177Lu-PSMA 617 in metastatic castrate-resistant prostate cancer.
Cited by 0
Semantic Scholar
Real-world ARPI utilization patterns and outcomes in metastatic castration-sensitive prostate cancer.
Cited by 0
Semantic Scholar
Real-world Bruton tyrosine kinase inhibitor (BTKi) use and clinical outcomes among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Cited by 1
OpenAlex
POSTER: CLL-411 Real-World Bruton Tyrosine Kinase Inhibitor Use and Clinical Outcomes Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Cited by 0
OpenAlex
Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment
Cited by 0
Semantic Scholar
Factors impacting treatment with abemaciclib + endocrine therapy in high risk early-stage HR+/HER2- breast cancer patients.
Cited by 0
Semantic Scholar
Real-world zanubrutinib treatment patterns in mantle cell lymphoma (MCL) among US community oncology patients with prior Bruton tyrosine kinase inhibitor (BTKi) therapy.
Cited by 0
Semantic Scholar
Research Topics
Chronic Lymphocytic Leukemia Research
(19)
Advanced Breast Cancer Therapies
(13)
PARP inhibition in cancer therapy
(9)
Cancer Treatment and Pharmacology
(8)
Lung Cancer Treatments and Mutations
(7)
Frequent Co-Authors
Affiliations
UPMC Health System
Magee-Womens Hospital
UPMC Hillman Cancer Center
University of Pittsburgh Medical Center
Colorado Center for Bone Research